News

The oil market will be well supplied. Negotiations regarding the terms with Iran remain indecisive. The Strait of Hormuz will be freely open, with nearly 2,000 vessels waiting to leave the Persian Gulf. President Trump will not accept a bad deal.

This move stems from pressure by the US government and oil and gas industry organizations, who previously warned that the regulation could affect Europe's ability to secure fuel supplies.

Regional medical insurance contractor Palmetto GBA has issued the final Local Coverage Determination (LCD), clearly including this technology within its coverage scope. The new policy is scheduled to take effect on July 5, 2026. The release of this final LCD marks a decisive step in the medical reimbursement process, paving the way for the use of NanoKnife IRE technology in treating eligible patients. The determination of coverage is expected to enhance both the accessibility and adoption rate of this innovative device in clinical settings.For AngioDynamics, this development is highly significant. Federal health insurance coverage is often a key catalyst for the wide-scale acceptance and commercial success of medical technologies. A clear reimbursement pathway not only alleviates the financial concerns of healthcare institutions but may also accelerate physician adoption of the technology, thereby potentially boosting revenue growth for the related product line.NanoKnife IRE is a non-thermal tumor ablation technology that uses high-voltage electrical pulses to destroy cancer cells, while aiming to preserve surrounding critical tissue structures such as blood vessels and nerves. This technology mainly targets certain tumor types that are difficult to treat with traditional surgery.With the implementation of the final coverage policy, AngioDynamics and its partners will be able to more clearly plan market promotion and patient access strategies. This move is expected to further strengthen the company's market position in the field of interventional oncology treatment.